Efficacy evaluation on switching to 50mg of minodronic acid hydrate in patients with osteoporosis

Efficacy evaluation on switching to 50mg of minodronic acid hydrate in patients with osteoporosis - A study for effects on switching to minodronic acid hydrate in patients with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012226

Enrollment

100

Registered

2013-11-06

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Patients included are to be given 50 mg of minodronic acid hydrate once every 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients on medication with bisphosphonates (other than monodronic acid) diagnosed with primary osteoporosis -Patients who consent to their participation in the study and can answer questionnaires

Exclusion criteria

Exclusion criteria: Patients who have withdrawn their consent to participation in the study -Patients who discontinued their medication with minodronic acid hydrate

Design outcomes

Primary

Measure	Time frame
Changes in bone mineral density	—

Secondary

Measure	Time frame
-Changes in bone metabolic markers -Changes in pain symptoms -Changes in abdominal symptoms -Changes in patients will for medication	—

Countries

Japan

Contacts

Public Contactkoichiro morishita

Yokkaichi Social Insurance Hospital Department of Orthopedic Surgery

seikeiteam@yahoo.co.jp059-331-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026